Article

Personalized Mouse TumorGrafts to Evaluate Treatment Benefits

Icahn School of Medicine at Mount Sinai and Champions Oncology have initiated a study evaluating TumorGrafts' ability to predict treatment benefit in patients with triple-negative breast cancer. A side-by-side genomic analysis of patients' tumor and TumorGraft mouse avatars, before and after treatment, will also be conducted.

Icahn School of Medicine at Mount Sinai and Champions Oncology, a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced the initiation of a clinical trial evaluating the use of Champions TumorGrafts® in 100 patients with triple-negative breast cancer. The study will also include a side-by-side genomic analysis of the patients' tumor and TumorGraft mouse avatars before and after treatment. Principal investigators from the Dubin Breast Center and Icahn Institute for Genomics are leading this effort at Mount Sinai, and the project is being coordinated through the Tisch Cancer Institute.

"Mount Sinai is at the forefront of new advancements and innovation in breast cancer treatment," said Elisa Port, MD, Chief of Breast Surgery and Director of Dubin Breast Center at The Mount Sinai Hospital. "This trial is one of several looking at a more individualized approached to treating breast cancer patients. These findings will provide invaluable information on the best course of treatment for the individual instead of a one size fits all approach."

Press release: http://on.mktw.net/1i6evOZ

Source: MarketWatch

Related Videos
Corey McEwen, PharmD, MS
dr linda bosserman
dr andrew leitner
Glenn Balasky during a video interview
dr joseph alvarnas
dr joseph alvarnas
Neal D. Shore, MD
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo